Interestingly, when we matched gefitinib sensitivity to BIM and mTOR mRNA and protein expression in EGFR-mutant lung adenocarcinoma cell lines, we observed that the IC50 values of gefitinib increase as the mTOR levels increase in the three sensitive and high BIM expressing cell lines (PC-9, H3255 and 11–18 in Fig. 4). This evidence concerns the gene BCL2L11 and lung adenocarcinoma.